Last reviewed · How we verify
Single intravenous doses of MRX-4
Single intravenous doses of MRX-4 is a Small molecule drug developed by MicuRx. It is currently in Phase 1 development.
At a glance
| Generic name | Single intravenous doses of MRX-4 |
|---|---|
| Sponsor | MicuRx |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single intravenous doses of MRX-4 CI brief — competitive landscape report
- Single intravenous doses of MRX-4 updates RSS · CI watch RSS
- MicuRx portfolio CI
Frequently asked questions about Single intravenous doses of MRX-4
What is Single intravenous doses of MRX-4?
Single intravenous doses of MRX-4 is a Small molecule drug developed by MicuRx.
Who makes Single intravenous doses of MRX-4?
Single intravenous doses of MRX-4 is developed by MicuRx (see full MicuRx pipeline at /company/micurx).
What development phase is Single intravenous doses of MRX-4 in?
Single intravenous doses of MRX-4 is in Phase 1.
Related
- Manufacturer: MicuRx — full pipeline
- Compare: Single intravenous doses of MRX-4 vs similar drugs
- Pricing: Single intravenous doses of MRX-4 cost, discount & access